gutflix
GI learning, personalised

Summary

A NEW HEMOSTATIC DEVICE COAJET® FOR GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION: RANDOMIZED SINGLE CENTER STUDY

Seong Woo Jeon

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

A prospective randomized trial of 56 patients found that Coajet®, a new monopolar hemostatic device with an integrated injection needle, achieved comparable efficacy to conventional hemostatic forceps for bleeding control during gastric endoscopic submucosal dissection with shorter procedure times.

KEY POINTS

- Total operation time was shorter with Coajet® compared to Hemograsper® (12.36 ± 6.73 vs. 15.97 ± 6.92 minutes, p = 0.05), and hemostasis time also trended shorter (130.4 ± 81.49 vs. 186.6 ± 134.5 seconds, p = 0.06).
- Complete en bloc resection rate, admission days, grade of immediate bleeding, and delayed bleeding within 30 days (one case in each group) showed no significant differences between the two devices.
- Baseline patient characteristics including age, sex, diagnosis, lesion locations, endoscopic sizes, and morphology were comparable between groups.
- This single-center study enrolled 56 consecutive patients undergoing gastric ESD between February 2022 and January 2023, with Coajet® also used for lesion marking and submucosal injection in the intervention group.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/c1b7c1b6-743b-11ee-acdd-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.